News & SEC Filings

View the latest news and SEC filings

News

RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.

SEC Filings

Date Form Filing Group

August 17, 2022

Initial filing by director officer or owner of more than ten percent.

3

3,4,5

August 12, 2022

An amendment to a SC 13D filing

SC 13D/A

Other

August 12, 2022

Report of unscheduled material events or corporate event

8-K

Current Reports

August 11, 2022

Statement of changes in beneficial ownership of securities

4

3,4,5

August 11, 2022

Statement of changes in beneficial ownership of securities

4

3,4,5

August 11, 2022

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

424B5

Registration Statements

August 11, 2022

An amendment to a SC 13D filing

SC 13D/A

Other

August 10, 2022

An amendment to the SC 13G filing

SC 13G/A

Other

August 9, 2022

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

424B5

Registration Statements

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.

Close up of female doctor hold woman patient hands help on personal therapy session, psychologist or counselor show understanding and care, support depressed suffering client on treatment